| Term 
 | Definition 
 
        |   
Neuronal type, ganglion receptorPentamer of (9) α and (3) β subunitsLocated in postganglionic cell body and dendrites, some presynaptic Ach terminalsBinding --> Open Na, K channel --> depolarization |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
Muscle type, end plate receptorFound in skeletal muscle end platesBinding --> opening of Na, K channels --> depolarization   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Located in nerves: CNS, sympathetic postganglionic, some presynaptic   Ligand binding --> formation of IP3 and DAG --> increased intracellular calcium |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Located in myocardium, smooth muscle, some presynaptic sites Acts through Gi Ligand binding --> opening of K+ channels + inhibition of adenylyl cyclase --> decreased cAMP |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Located in exocrine glands, smooth muscle, and vessels with smooth muscle Act through Gq Binding --> formation of IP3 and DAG --> increased intracellular calcium |  | 
        |  | 
        
        | Term 
 
        | Muscarinic Receptor Agonists |  | Definition 
 
        | Choline esters - acetylcholine Cholinomimetic alkaloids - muscarine, pilocarpine   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Muscarinic receptor agonist Permanently charged quarternary ammonium --> poorly absorbed, can't get into CNS Hydrolyzed by acetylcholinesterase Binding to nicotinic receptors inhibited by β group --> selective Not used therapeutically |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Muscarinic receptor agonist - choline ester Used to diagnose asthma   Carbamic acid derivative - resistant to Achesterase hydrolysis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Muscarinic receptor agonist - choline ester Used topically as miotic agent Glaucoma treatment Carbamic acid derivative - resistant to Achesterase hydrolysis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Muscarinic receptor agonist - choline ester Used to promote GI and urinary tract motility (must be due to non-obstructive cause)   Usually used post-operative or post-partum |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Cholinomimetic alkaloids Quaternary amine --> poorly absorbed Not used frequently |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Muscarine receptor agonist -  Cholinomimetic alkaloid 
 Tertiary amine --> not hydrolyzed by Achesterase Well absorbed, penetrates CNS Excreted by kidney 
 Used as treatment for Sjogren's (sialogogue), miotic agent |  | 
        |  | 
        
        | Term 
 
        | Effects of muscarinic agonists |  | Definition 
 
        | Cardiac slowing, decrease in CO, vasodilation --> fall in arterial pressure Increase in GI peristalsis, contraction of bladder and bronchial smooth muscle Stimulation of sweat, lacrimation, salivation, bronchial secretion Contraction of ciliary muscle (lowers intraocular pressure, good for acute glaucoma) |  | 
        |  | 
        
        | Term 
 
        | Toxicity of muscarinic agents |  | Definition 
 
        | Nausea and vomiting Salivation Sweating Cutaneous vasodilation Bronchial constriction Treat with atropine   Some poisonous mushrooms contain muscarine, effects in 15-30 mins |  | 
        |  | 
        
        | Term 
 
        | Muscarinic Receptor Antagonists |  | Definition 
 
        | Little selectivity Same basic structure as Ach, with aromatic in place of acetyl group |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Competitive muscarinic antagonist Tertiary amine Found in belladonna/nightshade   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Competitive muscarinic antagonist Similar structure to atropine Well absorbed from gut, conjunctival membrane Significant CNS absorptio --> sedation 
 Formulated for transdermal absorption (motion sickness) Ameliorate nausea from chemotherapy 
 Duration of effect: 3 to 7 days 
 
 |  | 
        |  | 
        
        | Term 
 
        | Pharmacological effects of atropine |  | Definition 
 
        | Dry as a bone, blind as a bat, red as a beet, mad as a hatter Inhibition of secretions - salivary, bronchial, lacrimal, sweat Tachycardia - inhibits parasympathetic tone Mydriasis - dilation of pupil Cycloplegia - paralysis of accomodation Inhibition of GI motility Relaxation of bronchial, biliary, urinary smooth muscle Excitatory effects on CNS 
 Duration of effects: 7 to 10 days |  | 
        |  | 
        
        | Term 
 
        | Therapeutic uses for atropine |  | Definition 
 
        | Induce myadriasis for opthalmologic exam Reverse sinus bradycardia Inhibit excessive salivation/mucus  Prevent vagal reflex Counteract effects of muscarine poisoning |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Competitive muscarinic receptor antagonist Tertiary amine Adjunct in therapy of Parkinsons Used to treat acute dystonia caused by antipsych meds |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Competitive antagonist of muscarinic receptor Quaternary amine --> low CNS penetration Used to decrease oral secretion Decrease GI spasm Treat peptic ulcer Prevent bradycardia |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Competitive antagonist of muscarinic receptor M3 specificity Tertiary amine   Relief of bladder spasm of urological surgery |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Competitive antagonist of muscarinic receptor M3 selectivity Tertiary amine Similar to darifenacin, xerostomia Used for urinary incontinence |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Competitive inhibitor of muscarinic receptor Synthetic analog of atropine Little effect on smooth muscle/CNS   Used in peptic ulcer disease |  | 
        |  | 
        
        | Term 
 
        | Clinical Uses of Muscarinic Antagonists |  | Definition 
 
        | Cardiovascular - atropine for bradycardia Opthalmic - tropicamide - dilate a pupil Neuro - scopolamine for motion sickness, benzotropine for parkinsonism Respiratory - iaptropium for COPD, asthma |  | 
        |  | 
        
        | Term 
 
        | Nicotinic Receptor Agonists |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Nicotinic receptor agonist Liquid .: easily absorbed across all surfaces Acute nicotine toxicity - 40 mg Ingestion -> vomiting   CNS stimulation:  seizures, coma, respiratory paralysis, hypertension, arrhythmia |  | 
        |  | 
        
        | Term 
 
        | Nicotinic Receptor Antagonists |  | Definition 
 
        | Ganglion blocking drugs Neuromuscular blocking drugs |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Type of nicotinic receptor antagonist Used to be used for HTN, too much toxicity   Toxicity: cycloplegia, orthostatic hypotension, constipation, urinary retention, sexual dys. |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Ganglion blocking drug, nicotinic receptor antagonist Used occasionally in treatment of hypertensive emergencies or dissecting aortic aneurysm |  | 
        |  | 
        
        | Term 
 
        | Neuromuscular Blocking Drugs   |  | Definition 
 
        | Type of nicotinic receptor antagonist Facilitate surgery, esp intraabd or intrathoracic Used to control ventilation |  | 
        |  | 
        
        | Term 
 
        | Neuromuscular blocking drugs Nicotinic antagonists |  | Definition 
 
        | Nondepolarizing neuromuscular blocking drugs Type of nicotinic receptor antagonist Block Ach from binding to receptor Prevent depolarization Block channel in its closed position |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Nicotinic antagonist Non depolarizing neuromuscular blocking drug Isoquinoline derivative |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Nondepolarizing neuromuscular blocking drug Nicotinic antagonist   Steroid derivative |  | 
        |  | 
        
        | Term 
 
        | Nicotinic agonists - mechanism |  | Definition 
 
        | More nicotinic agonists → Increased receptor stimulation → Channel stuck open → Continuous depolarization → Inactivation of voltage gated sodium channels → Paralysis   Can occur with anything that overwhelms the receptor Examples: acetylcholine, succinylcholine   
   |  | 
        |  | 
        
        | Term 
 
        | Nicotinic agonists - Pharmacology |  | Definition 
 
        | 1-2 quaternary nitrogens → poorly lipid-soluble Limit CNS entry Highly polar Inactive orally - must be administered parenterally Volume distribution only slightly larger than plasma volume |  | 
        |  | 
        
        | Term 
 
        | Major chemical classes of nondepolarizing drugs |  | Definition 
 
        | Isoquinoline derivatives - tubocurarine Steroid derivatives - pancuronium |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Two molecules of Ach linked end to end Slowly hydrolyzed by acetylcholinesterase Quickly eliminated by plasma cholinesterase Short duration of action (5 to 10 mins)   |  | 
        |  | 
        
        | Term 
 
        | Cholinesterase Inhibitors - Mechanism |  | Definition 
 
        | Bind to and inhibit acetylcholinesterase Increase level of acetylcholine in synaptic cleft Activate cholinergic receptors without directly binding to them   |  | 
        |  | 
        
        | Term 
 
        | Classes of Cholinesterase Inhibitors |  | Definition 
 
        | Simple alcohol - edrophonium Carbamic acid ester - neostigmine, physostigmine Organophosphates |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Simple alcohol - cholinesterase inhibitor Quaternary ammonium Reversible inhibitor of AchE Bnds reversibly via electrostatic interactions and hydrogen bonds Short duration of action - enzyme inhibitor complex persists for 2 to 10 minutes (allows for tight control)   
 |  | 
        |  | 
        
        | Term 
 
        | Therapeutic of edrophonium |  | Definition 
 
        | Diagnostic test for patients with muscle weakness Assesses adequacy of treatment for myasthenia gravis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Absorption poor due to permanent charge Negligible CNS distribution |  | 
        |  | 
        
        | Term 
 
        | Cholinesterase inhibitors for Alzheimers |  | Definition 
 
        | Tacrine Donepezil Rivastigmine Galantamine |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Anticholinesterase used for Alzheimer's Improves cognitive function Efficacy modest Significant hepatic toxicity |  | 
        |  |